Silver Book Fact

Prescription eye drops could delay or prevent half of glaucoma cases in African Americans.

Higginbotham, Eve J., Mae O. Gordon, Julie A. Beiser, Michael V. Drake, G. Richard Bennett, M. Roy Wilson, and Michael A. Kass. The Ocular Hypertension Treatment Study: Topical medication delays or prevents primary open-angle glaucoma in African American individuals. Archives of Ophthalmology. 2004; 122(6): 813-20. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=15197055&dopt=AbstractPlus

Reference

Title
The Ocular Hypertension Treatment Study: Topical medication delays or prevents primary open-angle glaucoma in African American individuals
Publication
Archives of Ophthalmology
Publication Date
2004
Authors
Higginbotham, Eve J., Mae O. Gordon, Julie A. Beiser, Michael V. Drake, G. Richard Bennett, M. Roy Wilson, and Michael A. Kass
Volume & Issue
Volume 122, Issue 6
Pages
813-20
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • DR Treatment Reduced Risk of Blindness
    Appropriate treatment can reduce the risk of blindness or moderate vision loss from DR by more than 90%.  
  • In general, every 10 mmHg reduction in systolic blood pressure reduces the risk of diabetes complications by 12%.  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.  
  • Screening and treatment for diabetic retinopathy in type 2 diabetes patients produces annual savings of 53,986 person-years of sight.